Corruption and Medicine Quality in Latin America: A Pilot Study
-
Roger Bate
Abstract
Fake and substandard medicines are a significant problem in developing nations, and a growing problem in developed ones too. There have been assessments of basic medicine quality from many countries and regions across the world but almost none in Central and South America. Over the past decade, as part of our research, we have collected over ten thousand samples of medicines from 22 cities in emerging markets, but the only one from the Latin region was Sao Paolo in Brazil. We have now rectified this gap, at least for one critical medicine, the broad spectrum antibiotic ciprofloxacin. Using original, self-collected data from ten countries in Latin America, we test whether the 687 Ciprofloxacin treatments pass the Global Pharma Health Fund e.V. Minilab® protocol to identify substandard or counterfeit medicines. In terms of quality, 93 percent of drugs were good quality. Within the drugs that failed the quality test, the majority were substandard rather than fake. About 26 % of the poor quality drugs were fake, with zero active pharmaceutical ingredient (API), while the rest were substandard, with less than 80 % API. In line with results from our earlier studies, we find that products that were locally registered, as well as those with SRA or WHO pre-qualification, were more likely to pass the test. A new finding in this paper is that corruption is a key predictor of poor quality drugs. Less corrupt countries had higher levels of passing drugs.
Funding statement: The funding for data collection and testing was made by two main sources, Legatum Institute and Reason Foundation.
References
Afzar, O., and T. Gurgur. 2008. “Does Corruption Affect Health and Education Outcomes in the Philippines?” Economics of Governance 9(3):197–244.10.1007/s10101-006-0031-ySuche in Google Scholar
Akunyili, D. (2006). The Fight against Counterfeit Drugs in Nigeria. In Transparency International, Global Corruption Report 2006.Suche in Google Scholar
Attaran, A., D. Barry, S. Basheer, R. Bate, D. Benton, J. Chauvin, and M. McKee. 2012. “How to Achieve International Action on Falsified and Substandard Medicines.” British Medical Journal 345:e7381.10.1136/bmj.e7381Suche in Google Scholar
Bate, R. 2012. Phake: The Deadly World of Falsified and Substandard Medicines. Washington, DC: AEI Press.10.1111/j.1468-0270.2012.02184.xSuche in Google Scholar
Bate, R., G.Z. Jin, and A. Mathur (2012). Counterfeit or Substandard? Assessing Price and Non- Price Signals of Drug Quality. (NBER Working Paper No. 18073). Cambridge, MA: National Bureau of Economic Research.10.3386/w18073Suche in Google Scholar
Bate, R., G.Z. Jin, and A. Mathur. 2015. “Falsified or Substandard? Assessing Price and Non-Price Signals of Drug Quality.” Journal of Economics and Management Strategy 24 (24): 687–711.10.1111/jems.12114Suche in Google Scholar
Bate, R., G.Z. Jin, A. Mathur, and A. Attaran. 2016. “Poor-Quality Drugs and Global Trade: A Pilot Study.” American Journal of Heath Economics 2(3):373–398.10.1162/AJHE_a_00049Suche in Google Scholar
Bate, R., L. Mooney, and K. Hess. 2010. “Medicine Registration and Medicine Quality: A Preliminary Analysis of Key Cities in Emerging Markets.” Research and Reports in Tropical Medicine 1:89–93.10.2147/RRTM.S15199Suche in Google Scholar
Bate, R., E. Putze, S. Naoshy, A. McPherson, and L. Mooney (2010). Drug Registration - a Necessary but Not Sufficient Condition for Good Quality Drugs – A Preliminary Analysis of 12 Countries. (Working Paper). Congella, South Africa: Africa Fighting Malaria.Suche in Google Scholar
Caudron, J.M., N. Ford, M. Henkens, C. Mace, R. Kiddle-Monroe, and J. Pin. 2008. “Substandard Medicines in Resource-Poor Settings: A Problem that Can No Longer Be Ignored.” Tropical Medicine & International Health 13 (8): 1062–1072.10.1111/j.1365-3156.2008.02106.xSuche in Google Scholar
Cockburn, R., P.N. Newton, E.K. Agyarko, D. Akunyili, and N.J. White. 2005. “The Global Threat of Counterfeit Drugs: Why Industry and Governments Must Communicate the Dangers.” Plos Med 2 (4): 302–308.10.1371/journal.pmed.0020100Suche in Google Scholar
Cohen, J.C. 2005. Pharmaceuticals and Corruption: A Risk Assessment. Washington, DC: World Bank.Suche in Google Scholar
Davoodi, H., S. Gupta, and E. Tiongson (2000). Corruption and the Provision of Health Care and Education Services. (IMF Working Paper No. 00/116). Washington, DC: International Monetary Fund.10.5089/9781451853926.001Suche in Google Scholar
Echeverría, J.F. 2016. Mejores Ciudades Para Hacer Negocios 2016. Coral Gables, FL: América Economía.Suche in Google Scholar
Global Health Intelligence (2016). Opportunities in Latin America’s Healthcare Sector: Looking Ahead to 2016. Retrieved from http://globalhealthintelligence.com/opportunities-in-latin-americas-healthcare-sector-2016/.Suche in Google Scholar
Hunt, J. (2007). Bribery in Health Care in Peru and Uganda. (NBER Working Paper No. 13034). Cambridge, MA: National Bureau of Economic Research.10.3386/w13034Suche in Google Scholar
Institute of Medicine. 2013. Countering the Problem of Falsified and Substandard Drugs. Washington, DC: National Academy of Sciences.Suche in Google Scholar
Jähnke, R.W.O., G. Küsters, and K. Fleischer. 2001. “Low-Cost Quality Assurance of Medicines Using the GPHF-Minilab.” Drug Information Journal 35: 941–945.10.1177/009286150103500333Suche in Google Scholar
Kohler, J.C., N. Mitsakakis, F. Saadat, D. Bynh, and M.G. Martinez. 2015. “Does Pharmaceutical Pricing Transparency Matter? Examining Brazil’s Public Procurement System.” Globalization and Health 11 (34): 1–13.10.1186/s12992-015-0118-8Suche in Google Scholar
Lewis, M. (2006) Governance and Corruption in Public Health Care Systems, Working Paper, Center for Global Development; Washington DC10.2139/ssrn.984046Suche in Google Scholar
Mackey, T.K., B.A. Liang, P. York, and T. Kubic. 2015. “Counterfeit Drug Penetration into Global Legitimate Medicine Supply Chains: A Global Assessment.” American Journal of Tropical Medicine and Hygiene 92(Suppl 6):59–67.10.4269/ajtmh.14-0389Suche in Google Scholar
Martin, A., and J.P. Spinetto. 2016. Can Paraguay Escape Decades of Despotism, Decades of Despotism, Ineptitude, and Ineptitude, and Corruption? Bloomberg, March 22. http://www.bloomberg.com/features/2016-paraguay-president-horacio-cartes/.Suche in Google Scholar
Morris, J., and P. Stevens. 2006. Counterfeit Medicines in Less Developed Countries. London: International Policy NetworkSuche in Google Scholar
Oxfam. (2011). Oxfam Annual Report 2010-2011. Oxford, United Kingdom.Suche in Google Scholar
Pugatch, M., D. Tortensson, and M. Laufer. 2015. The Next Frontier in Ensuring the Quality of Medicines. District of Columbia: Pugatch ConsiliumSuche in Google Scholar
Rose, R. (2006). Corruption Is Bad for Your Health: Findings from Central and Eastern Europe. In Transparency International, Global Corruption Report 2006.Suche in Google Scholar
Rose-Ackerman, S. (2015). Corruption in the Procurement of Pharmaceuticals and Medical Equipment in China: The Incentives Facing Multinationals, Domestic Firms and Hospital Officials. Yale Faculty Scholarship Series. Paper 4945.10.5070/P8321028003Suche in Google Scholar
Savedoff, W. (2007). Transparency and Corruption in the Health Sector: A Conceptual Framework and Ideas for Action in Latin American and the Caribbean. Sustainable Development Department, Inter-American Development Bank, Health Technical Note 03/2007.Suche in Google Scholar
Schargrodsky, E., J. Mera, and F. Weinschelbaum.2001. “Transparency and Accountability in Argentina’s Hospitals.” In Diagnosis Corruption: Fraud in Latin American Public Hospitals edited by R. Di Tella and W. Savedoff. Washington, DC: Inter-American Development Bank.Suche in Google Scholar
Tortensson, D., and M. Pugatch. 2010. What Lies Within?: Procurement Processes and the Risk of Substandard Medicines. Stockholm, Sweden: Stockholm NetworkSuche in Google Scholar
Transparency International. 2006. Global Corruption Report: Corruption in Health Berlin Germany: Transparency InternationalSuche in Google Scholar
Transparency International. 2015. Corruption Perceptions Index 2015 Berlin, Germany: Transparency InternationalSuche in Google Scholar
U.S. Trade Representative. (2016). Special 301 Report. Washington, DC: Office of the United States Trade Representative.Suche in Google Scholar
Vian, T. (2002). Corruption and the Health Care Sector: Sectoral Perspectives on Corruption. USAID, Washington, DC i-34.Suche in Google Scholar
Vian, T. 2008. “Review of Corruption in the Health Sector: Theory, Methods and Interventions.” Health Policy and Planning 23 (2): 83–94.10.1093/heapol/czm048Suche in Google Scholar
Webster, P.C. 2012. “Health in Colombia: A System in Crisis.” Canadian Medical Association Journal 184(6):E289–E290.10.1503/cmaj.109-4124Suche in Google Scholar
Wells, M. (2013, June 24). Criminals Flooding Paraguay with Counterfeit Drugs. InSight Crime. Retrieved from http://www.insightcrime.org/news-briefs/criminals-killing-paraguayans-with-counterfeit-drugs.Suche in Google Scholar
World Bank. xxxx. Poverty Net Tool and Practices Washington, DC: World BankSuche in Google Scholar
World Bank. xxxx. Logistics Performance Index 2016. Data File Washington, DC: World BankSuche in Google Scholar
© 2018 Walter de Gruyter GmbH, Berlin/Boston
Artikel in diesem Heft
- research-article
- The Heterogeneous Cyclicality of Income and Wages Among the Distribution in the UK
- Potential Parenthood and Career Progression of Men and Women – A Simultaneous Hazards Approach
- The Role of Adolescent Health in Adult SES Outcomes
- Corruption and Medicine Quality in Latin America: A Pilot Study
- Public–Private Monopoly
- Going Along or Going Independent? A Dynamic Analysis of Nonprofit Alliances
- Letter
- Are Busy Directors Harmful or Helpful? Evidence from the Great Recession
Artikel in diesem Heft
- research-article
- The Heterogeneous Cyclicality of Income and Wages Among the Distribution in the UK
- Potential Parenthood and Career Progression of Men and Women – A Simultaneous Hazards Approach
- The Role of Adolescent Health in Adult SES Outcomes
- Corruption and Medicine Quality in Latin America: A Pilot Study
- Public–Private Monopoly
- Going Along or Going Independent? A Dynamic Analysis of Nonprofit Alliances
- Letter
- Are Busy Directors Harmful or Helpful? Evidence from the Great Recession
